ticlopidine has been researched along with Diabetic Nephropathies in 8 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We sought to assess the impact of renal function on platelet reactivity in patients with diabetes mellitus (DM) and coronary artery disease on aspirin and clopidogrel therapy." | 3.76 | Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. ( Alfonso, F; Angiolillo, DJ; Bass, TA; Bernardo, E; Capodanno, D; Fernandez-Ortiz, A; Ferreiro, JL; Jimenez-Quevedo, P; Macaya, C; Sabaté, M; Ueno, M; Vivas, D, 2010) |
| "We present a case report of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) developing in a kidney/pancreas transplant recipient after the initiation of treatment with clopidogrel for symptomatic coronary artery disease." | 1.31 | Clopidogrel-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in a kidney/pancreas transplant recipient. ( Chinnakotla, S; Fidler, ME; Hammeke, MD; Leone, JP; Tarantolo, S, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ozyalvacli, ME | 1 |
| Uyeturk, U | 1 |
| Halicioglu, S | 1 |
| Kargı, E | 1 |
| Dasgupta, A | 1 |
| Steinhubl, SR | 1 |
| Bhatt, DL | 1 |
| Berger, PB | 1 |
| Shao, M | 1 |
| Mak, KH | 1 |
| Fox, KA | 1 |
| Montalescot, G | 1 |
| Weber, MA | 1 |
| Haffner, SM | 1 |
| Dimas, AP | 1 |
| Steg, PG | 1 |
| Topol, EJ | 1 |
| Angiolillo, DJ | 1 |
| Bernardo, E | 1 |
| Capodanno, D | 1 |
| Vivas, D | 1 |
| Sabaté, M | 1 |
| Ferreiro, JL | 1 |
| Ueno, M | 1 |
| Jimenez-Quevedo, P | 1 |
| Alfonso, F | 1 |
| Bass, TA | 1 |
| Macaya, C | 1 |
| Fernandez-Ortiz, A | 1 |
| Igaki, N | 1 |
| Matsuda, T | 1 |
| Yatani, H | 1 |
| Kawaguchi, T | 1 |
| Kida, A | 1 |
| Yanase, K | 1 |
| Moriguchi, R | 1 |
| Sakai, M | 1 |
| Tamada, F | 1 |
| Goto, T | 1 |
| Nyberg, G | 1 |
| Larsson, O | 1 |
| Westberg, NG | 1 |
| Aurell, M | 1 |
| Jagenburg, R | 1 |
| Blohmé, G | 1 |
| Chinnakotla, S | 1 |
| Leone, JP | 1 |
| Fidler, ME | 1 |
| Hammeke, MD | 1 |
| Tarantolo, S | 1 |
| Lang, J | 1 |
| Cao, H | 1 |
| Wei, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pragmatic Randomized Controlled Trial Comparing Treatment Effectiveness of Guideline Indicated Anti-platelet Therapy for Acute Coronary Syndrome in Patients With Chronic Kidney Disease[NCT03150667] | Phase 4 | 220 participants (Anticipated) | Interventional | 2017-04-10 | Recruiting | ||
| Platelet Reactivity in Patients With Chronic Kidney Disease Receiving Adjunctive Cilostazol Compared to a High-maintenance Dose of Clopidogrel[NCT01328470] | Phase 4 | 85 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for ticlopidine and Diabetic Nephropathies
| Article | Year |
|---|---|
Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] tri
Topics: Aspirin; Cardiovascular Diseases; Chi-Square Distribution; Clopidogrel; Diabetic Nephropathies; Drug | 2009 |
[Comparative study on effect of Panax notoginseng and ticlid in treating early diabetic nephropathy].
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Diabetic Nephropathies; Drugs, Chinese Herbal; Female; Ginsenos | 1998 |
6 other studies available for ticlopidine and Diabetic Nephropathies
| Article | Year |
|---|---|
Recommendations on the Clinical Use of Compound Danshen Dripping Pills.
Topics: Angina Pectoris; Aspirin; Camphanes; Clopidogrel; Coronary Disease; Diabetes Mellitus; Diabetic Neph | 2017 |
Spontaneous renal parenchymal hematoma associated with clopidogrel in a patient with diabetic nephropathy.
Topics: Aged; Clopidogrel; Diabetic Nephropathies; Hematoma; Humans; Kidney Diseases; Male; Platelet Aggrega | 2015 |
Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cross-Sectional Studies; Diabe | 2010 |
Deep venous thrombosis, myocardial infarction, and occlusion of vascular access associated with heparin-induced thrombocytopenia in a diabetic hemodialysis patient.
Topics: Anticoagulants; Catheters, Indwelling; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Fi | 2003 |
A platelet aggregation inhibitor--ticlopidine--in diabetic nephropathy: a randomized double blind study.
Topics: Adult; Creatinine; Diabetic Nephropathies; Double-Blind Method; Drug Evaluation; Female; Glomerular | 1984 |
Clopidogrel-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in a kidney/pancreas transplant recipient.
Topics: Adult; Clopidogrel; Coronary Disease; Cyclosporine; Diabetes Mellitus, Type 1; Diabetic Nephropathie | 2000 |